Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals

Liver International

Volumn 35, Issue s1, 2015, Pages 44-50

  Coilly, Audrey ^a,b,c,d   Roche, Bruno ^a,b,c,d   Duclos Vallée, Jean Charles ^a,b,c,d   Samuel, Didier ^a,b,c,d  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Universite Paris Sud   (France)

^d Hepatinov   (France)

Author keywords

Direct acting antivirals; Hepatitis C; Liver transplantation; Sofosbuvir; Treatment

Indexed keywords

PROTEASE INHIBITORS;

ADVERSE EFFECTS; COMPLICATION; DRUG EFFECTS; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; METHODS; RECURRENCE; TRENDS; VIRAL LOAD; VIROLOGY;

DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; PROTEASE INHIBITORS; RECURRENCE; VIRAL LOAD;

EID: 84919686294     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12728     Document Type: Review

References (29)

1. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): 69-78.
2. Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol 2013; 58: 287-96.
3. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33(Suppl. 1): 56-62.
4. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-41.
5. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32(4 Pt 1): 852-8.
6. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
7. Bizollon T, Pradat P, Mabrut JY, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007; 7: 448-53.
8. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-42.e4.
9. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-98.
10. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-38.
11. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
12. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-99.
13. Coilly A, Furlan V, Roche B, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56: 5728-34.
14. Forns X, Samuel D, Mutimer D, et al. P1185 interim SVR12 results from the telaprevir phase 3B replace study in treatment-naive stable liver transplant patients with genotype 1 HCV infection. J Hepatol 2014; 60: S481.
15. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
16. Burton JR Jr, O'leary JG, Verna EC, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014; 61: 508-514.
17. Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
18. Werner CR, Egetemeyr DP, Nadalin S, et al. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z Gastroenterol 2014; 52: 27-34.
19. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176-92.
20. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2014; doi: 10.1053/j.gastro.2014.09.023 [Epub ahead of print].
21. Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol 2014; 60: S28.
22. Fontana RJ, Hughes EA, Appelman H, et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053-9.
23. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-5.
24. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2014; doi: 10.1053/j.gastro.2014.10.001. [Epub ahead of print]
25. Forns X, Prieto M, Charlton M, et al. O62 sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. J Hepatol 2014; 60: S26.
26. Kwo P, Mantry P, Coakley E, et al. O114 results of the phase 2 study M12-999: interferon-free regimen of ABT-450/R/ABT-267 + ABT-333 + ribavirin in liver transplant recipients WITH recurrent HCV genotype 1 infection. J Hepatol 2014; 60: S47.
27. European Association for Study of Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
28. Carrion JA, Navasa M, Bosch J, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791-8.
29. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492-9.